FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)

Tourist behind 'escort' clip has left

The Chinese tourist who posted a video clip showing three Thai police officers offering her a shortcut through immigration and a police escort to her hotel in Pattaya has already left the country.

06:00

Time's up for MPs, no deal for Thaksin

Parties may propose a bill seeking to grant amnesty to convicts in politically related cases, but talks on the matter can only take place after the formation of a new parliament.

05:07

'Start over': Ukraine's Bakhmut evacuates as Russia claims to be nearing

BAKHMUT (UKRAINE) - Olena Morozova had endured months of bombardment in what has become the most gruelling battle of the war in Ukraine for the city of Bakhmut, but on Thursday, she said she had finally had enough.

04:45